Company news
Sangamo Therapeutics, Inc. news in 2019
Sangamo Therapeutics, Inc.'s news releases, calls and decks from 2019, newest first.
Sangamo Announces Early Completion of Transfer to Pfizer of SB-525 Hemophilia A Gene Therapy IND and an Earned $25 Million Milestone Payment
December 22, 2019
Sangamo Highlights Advancements in Genomic Medicine Pipeline and Expanded R&D and Manufacturing Capabilities at R&D Day
December 16, 2019
Sangamo to Highlight Genomic Medicine Pipeline, Technology Platforms, and Manufacturing Capabilities in December 17 R&D Day
December 5, 2019
Sangamo Therapeutics Appoints James R. Meyers to Its Board of Directors
November 25, 2019
Sangamo Therapeutics Announces New Scientific Advisory Board
November 7, 2019
Sangamo Therapeutics Reports Third Quarter 2019 Financial Results
November 5, 2019
Sangamo Therapeutics Appoints Sung Lee as Executive Vice President and Chief Financial Officer
October 31, 2019
Sangamo Therapeutics Announces Third Quarter 2019 Conference Call and Webcast
October 29, 2019
Sangamo Therapeutics Appoints Bettina M. Cockroft, MD, MBA, as Senior Vice President and Chief Medical Officer
September 29, 2019
Sangamo Therapeutics Appoints Gary H. Loeb as Executive Vice President and General Counsel
July 30, 2019
Sangamo Therapeutics Announces Second Quarter 2019 Conference Call and Webcast
July 30, 2019
Sangamo Announces Upcoming Presentation Of Investigational SB-525 Hemophilia A Gene Therapy Data At ISTH 2019
June 20, 2019
Sangamo Therapeutics Announces Participation In The Bank Of America Merrill Lynch 2019 Health Care Conference
May 9, 2019
Sangamo Therapeutics Announces First Quarter 2019 Conference Call And Webcast
April 30, 2019
Sangamo Therapeutics Announces Presentations At 2019 Annual Meeting Of The American Society Of Gene & Cell Therapy
April 14, 2019
Sangamo Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
April 7, 2019
Sangamo Therapeutics Announces Pricing of Public Offering of Common Stock
April 3, 2019
Sangamo Therapeutics Announces Proposed Public Offering of Common Stock
April 2, 2019
Sangamo Provides Clinical Development Update Including Early Phase 1/2 Beta Thalassemia Gene-edited Cell Therapy Data
April 1, 2019
Sangamo and Pfizer Announce Phase 1/2 Interim Data For Investigational Hemophilia A Gene Therapy
April 1, 2019
Sangamo Therapeutics To Host April 2, 2019 Conference Call To Provide Clinical Update
March 31, 2019